肿瘤血管双重靶向治疗：联合使用阿瓦斯汀与血管破坏剂（CA4P或OXi4503）。
Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503).
作者信息
Siemann Dietmar W, Shi Wenyin
机构信息
Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL 32610, USA.
出版信息
Anticancer Res. 2008 Jul-Aug;28(4B):2027-31.
Abstract
BACKGROUND
This study evaluated the therapeutic efficacy of combining vascular disrupting agents with antiangiogenic agents.
MATERIALS AND METHODS
Human clear cell renal carcinoma (Caki-1) tumors were established in nude mice. Treatments consisted of Avastin (2 mg/kg) administered twice a week; CA4P (100 mg/kg) or OXi4503 (25 mg/kg) administered 3 times a week for a period of 2 weeks; or a combination of Avastin and CA4P or OXi4503. Tumor response was assessed by growth delay.
RESULTS
The tumor growth delays were 8, 6, and 18 days for Avastin, CA4P, and OXi4503, respectively. When the two therapies were combined, there was a significantly greater tumor response than what was achieved with single-agent treatments. For example, Avastin plus CA4P led to a growth delay of 13 days, and 27 days for Avastin plus OXi4503.
CONCLUSION
Vascular-directed therapies that include both antiangiogenic and vascular disrupting therapeutics can result in significantly enhanced antitumor effects.
摘要
背景
本研究评估了血管破坏剂与抗血管生成剂联合使用的治疗效果。
材料与方法
在裸鼠体内建立人透明细胞肾癌细胞（Caki-1）肿瘤模型。治疗方案包括：阿瓦斯汀（2毫克/千克）每周给药两次；CA4P（100毫克/千克）或OXi4503（25毫克/千克）每周给药3次，持续2周；或阿瓦斯汀与CA4P或OXi4503联合使用。通过肿瘤生长延迟评估肿瘤反应。
结果
阿瓦斯汀、CA4P和OXi4503的肿瘤生长延迟分别为8天、6天和18天。当两种疗法联合使用时，肿瘤反应明显大于单药治疗。例如，阿瓦斯汀加CA4P导致生长延迟13天，阿瓦斯汀加OX47加OXi4503导致生长延迟27天。
结论
包括抗血管生成和血管破坏疗法的血管靶向治疗可显著增强抗肿瘤效果。
相似文献
1
Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503).
Anticancer Res. 2008 Jul-Aug;28(4B):2027-31.
2
Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate.
Anticancer Res. 2003 Mar-Apr;23(2B):1433-40.
3
Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique.
Eur J Cancer. 2006 Nov;42(17):3073-8. doi: 10.1016/j.ejca.2006.06.016. Epub 2006 Sep 7.
4
Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents.
Int J Mol Sci. 2020 Jul 6;21(13):4778. doi: 10.3390/ijms21134778.
5
Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity.
Clin Cancer Res. 2006 Jul 1;12(13):4090-4. doi: 10.1158/1078-0432.CCR-06-0163.
6
Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models.
Mol Cancer Ther. 2009 Oct;8(10):2872-81. doi: 10.1158/1535-7163.MCT-09-0583.
7
Leukemia regression by vascular disruption and antiangiogenic therapy.
Blood. 2010 Sep 2;116(9):1539-47. doi: 10.1182/blood-2009-06-230474. Epub 2010 May 14.
8
Preclinical evaluation of vascular-disrupting agents in Ewing's sarcoma family of tumours.
Eur J Cancer. 2009 Mar;45(4):713-22. doi: 10.1016/j.ejca.2008.11.045. Epub 2009 Jan 10.
9
Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity.
Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15040-5. doi: 10.1073/pnas.0807055105. Epub 2008 Sep 25.
10
From theoretical synergy to clinical supra-additive toxicity.
J Clin Oncol. 2009 Mar 20;27(9):1359-61. doi: 10.1200/JCO.2008.20.8595. Epub 2009 Feb 17.
引用本文的文献
1
Evaluating Therapeutic Efficacy of the Vascular Disrupting Agent OXi8007 Against Kidney Cancer in Mice.
Cancers (Basel). 2025 Feb 24;17(5):771. doi: 10.3390/cancers17050771.
2
Targeting the Tumor Vascular Supply to Enhance Radiation Therapy Administered in Single or Clinically Relevant Fractionated Schedules.
Int J Mol Sci. 2024 Jul 24;25(15):8078. doi: 10.3390/ijms25158078.
3
Targeting vascular disrupting agent-treated tumor microenvironment with tissue-penetrating nanotherapy.
Sci Rep. 2024 Jul 30;14(1):17513. doi: 10.1038/s41598-024-64610-7.
4
Multi-parametric investigations on the effects of vascular disrupting agents based on a platform of chorioallantoic membrane of chick embryos.
Quant Imaging Med Surg. 2024 Feb 1;14(2):1729-1746. doi: 10.21037/qims-23-1065. Epub 2024 Jan 23.
5
Demonstrating Tumor Vascular Disrupting Activity of the Small-Molecule Dihydronaphthalene Tubulin-Binding Agent OXi6196 as a Potential Therapeutic for Cancer Treatment.
Cancers (Basel). 2022 Aug 30;14(17):4208. doi: 10.3390/cancers14174208.
6
Computational-Based Discovery of the Anti-Cancer Activities of Pyrrole-Based Compounds Targeting the Colchicine-Binding Site of Tubulin.
Molecules. 2022 Apr 30;27(9):2873. doi: 10.3390/molecules27092873.
7
Imaging-Guided Evaluation of the Novel Small-Molecule Benzosuberene Tubulin-Binding Agent KGP265 as a Potential Therapeutic Agent for Cancer Treatment.
Cancers (Basel). 2021 Sep 24;13(19):4769. doi: 10.3390/cancers13194769.
8
Utilisation of Chick Embryo Chorioallantoic Membrane as a Model Platform for Imaging-Navigated Biomedical Research.
Cells. 2021 Feb 22;10(2):463. doi: 10.3390/cells10020463.
9
Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study.
Gynecol Oncol. 2020 Oct;159(1):79-87. doi: 10.1016/j.ygyno.2020.07.015. Epub 2020 Jul 26.
10
Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review.
Pharmaceuticals (Basel). 2020 Jan 3;13(1):8. doi: 10.3390/ph13010008.
本文引用的文献
1
An update on the clinical development of drugs to disable tumor vasculature.
Expert Opin Drug Discov. 2007 Oct;2(10):1357-67. doi: 10.1517/17460441.2.10.1357.
2
Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals.
Chem Res Toxicol. 2007 Dec;20(12):1885-94. doi: 10.1021/tx7002195. Epub 2007 Oct 18.
3
Antiangiogenesis and vascular endothelial growth factor/vascular endothelial growth factor receptor targeting as part of a combined-modality approach to the treatment of cancer.
Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S64-6. doi: 10.1016/j.ijrobp.2007.04.093.
4
Characterizing the tumor response to treatment with combretastatin A4 phosphate.
Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):211-7. doi: 10.1016/j.ijrobp.2006.12.051.
5
Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity.
Clin Cancer Res. 2006 Jul 1;12(13):4090-4. doi: 10.1158/1078-0432.CCR-06-0163.
6
Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474.
In Vivo. 2005 Nov-Dec;19(6):1045-50.
7
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
J Clin Oncol. 2005 Nov 1;23(31):8033-40. doi: 10.1200/JCO.2005.01.9661.
8
Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.
J Clin Oncol. 2005 Oct 1;23(28):7135-42. doi: 10.1200/JCO.2005.16.139.
9
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
J Clin Oncol. 2005 Aug 20;23(24):5578-87. doi: 10.1200/JCO.2005.07.120. Epub 2005 Jul 11.
10
Disrupting tumour blood vessels.
Nat Rev Cancer. 2005 Jun;5(6):423-35. doi: 10.1038/nrc1628.
Zotero 插件